Novartis Presents First-of-its-Kind Histology Data with Iscalimab (CFZ533) Suggesting the Extended Survival of Transplanted Organs May be Possible

Basel, June 6, 2019 - Novartis announced today new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the durability of transplanted kidneys as well as...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials